Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites

Nazartinib (EGF816, NZB) is a promising third-generation human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This novel irreversible mutant-selective EGFR inhibitor targets EGFR containing both the resistance mutation (T790M) and the activating mutations (L858R and Del19), while...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhameed, Ali S., Attwa, Mohamed W., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731747/
https://www.ncbi.nlm.nih.gov/pubmed/31598253
http://dx.doi.org/10.1098/rsos.190852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731747/
https://www.ncbi.nlm.nih.gov/pubmed/31598253
http://dx.doi.org/10.1098/rsos.190852

Ejemplares similares